Hill Dickinson advises Pharma C Investments plc on admission to Access segment of the AQSE Growth Market

Hill Dickinson’s Corporate team has recently advised its client, Pharma C Investments plc, on the admission of its entire issued capital to the Access segment of the AQSE Growth Market, which is operated by Aquis Stock Exchange Limited.

Pharma C is a medicinal cannabis investment vehicle, which will now look to identify investment opportunities in the medicinal cannabis sector, having raised £1 million prior to admission.

The company will focus on identifying investment opportunities in companies that provide ancillary products and services that serve medicinal cannabis sectors, not just in Europe but in markets globally (with a particular focus on the United Kingdom, Europe and Israel). The company will look to invest in countries that are internationally recognised as having well-developed and reputable laws and regulations for the research and production of medicinal cannabis and comply with the United Nations’ conventions on narcotics. The company expects to provide investee companies with strategic insights, and operational support to help them realise and execute their growth strategy. 

The Hill Dickinson team was led by associate Paul Jackson with assistance from paralegals Sanne Gerdsen and Vruksha Patel.

Chana Greenberg, chief executive officer, Pharma C, said: “This listing marks a significant milestone for Pharma C Investments and will provide the market with the opportunity to be part of an investment vehicle led by strong entrepreneurs and focused on the profitable and robust ancillary market in the medicinal cannabis sector”.